Article Text
Therapeutics
Randomised controlled trial
Oral treatment of acute pulmonary embolism with a fixed dose of rivaroxaban is non-inferior to standard treatment
Statistics from Altmetric.com
Footnotes
-
Competing interests AN has received lecture fees from Boehringer Ingelheim, served on an advisory board for Boehringer Ingelheim and received travel fees from Boehringer Ingelheim, Daiichi Sankyo and Pfizer.